Insulin icodec
Insulin icodec is an investigational ultralong-acting basal insulin analogue that is developed by Novo Nordisk. It has a plasma half-life more than eight days (compared to 25 hours of the previous longest-acting insulin analogue insulin degludec), making it a once-weekly basal insulin. The substance is composed of two peptide chains, linked by a disulfide bridge. The 21 amino acid residue chain has two internal disulfide bridges and the second chain is 29 residues long. Insulin icodec is the international nonproprietary name. Research 
Based on a clinical trial, glycemic control was found to be non-inferior with once-weekly insulin icodec compared with once-daily insulin glargine U100. References 

Experimental drugs
Insulin therapies